Helen of Troy Q1
This article was originally published in The Rose Sheet
Executive Summary
Firm posts 11.3% increase in revenue to $160.2 mil. and profit jump of 27% to $18.4 mil. in first fiscal 2010 quarter ended May 31, attributed to recent acquisitions of Infusium 23, Pert Plus and Sure (1"The Rose Sheet" March 15, 2010, In Brief). El Paso, Texas firm recorded revenue of $112.2 in its personal-care segment, up nearly 11% from the same quarter a year ago. Helen of Troy plans integration and development of new Pert Plus and Sure product lines in this fiscal year while pursuing "additional acquisitions of complementary businesses or product lines," according to July 8 release
You may also be interested in...
Helen of Troy gets Sure, Pert Plus
El Paso, Texas-based company expects acquisition of Innovation Brands' Pert Plus hair-care and Sure antiperspirant/deodorant brands to be accretive upon integration, generating roughly $65 mil. for its Idelle Labs division. Firm hails Pert Plus as a leader in the $2 bil. U.S. shampoo sector "through its pioneering development of the 2-in-1 shampoo and conditioner combination." Recently launched Pert Plus 3-in-1 products (shampoo plus conditioner plus body wash) offer efficiencies for the whole family and for men (1"The Rose Sheet" March 1, 2010, Marketing In Brief). Meanwhile, Sure is "one of the leading brands in the $1.7 bil. U.S. antiperspirant and deodorant category," Helen of Troy says. "Adding [the brands] will enhance our role as a comprehensive provider of solutions for our hair-care and personal grooming consumers and styling professionals." Deal is expected to close by the end of the month, according to March 10 release. Helen picked up Infusium 23 hair care from Procter & Gamble last spring (2"The Rose Sheet" April 6, 2009, In Brief). Its personal-care portfolio also includes Brut men's grooming, Ogilvie hair-straightening treatments and Sea Breeze astringents
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.